Gastroparesis Pipeline
Gastroparesis Pipeline
Gastroparesis Pipeline Shows Strong Momentum With 8+ Key Pharma Companies Advancing Novel Therapies | DelveInsight
DelveInsight’s “Gastroparesis Pipeline Insight, 2025” report delivers an in-depth evaluation of more than 8 leading companies and 10+ investigational drugs shaping the Gastroparesis treatment landscape. The report provides a detailed overview of both clinical and preclinical candidates, along with a comprehensive therapeutic assessment based on product type, development stage, route of administration, and molecular classification. Additionally, it highlights discontinued and dormant pipeline assets within the space.
Gain a competitive edge with the most up-to-date intelligence. Access DelveInsight’s detailed Gastroparesis Pipeline Report to analyze upcoming therapies, strategic players, and the future direction of treatment innovations: https://www.delveinsight.com/report-store/gastroparesis-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=mpr
Key Highlights from the Gastroparesis Pipeline Report
- In June 2025, CinDome Pharma Inc. initiated a clinical study to assess the efficacy of CIN-102 (deudomperidone) in reducing symptoms associated with diabetic gastroparesis in adult patients.
- DelveInsight’s analysis indicates a dynamic and expanding pipeline, with 8+ active companies developing over 10 promising therapies for Gastroparesis management.
- Major Gastroparesis companies include Neurogastrx Inc., Dr. Falk Pharma GmbH, CinDome Pharma Inc., Entero Therapeutics Inc., RaQualia Pharma, and others.
- Notable pipeline candidates include Tradipitant, PCS12852, Naronapride, CNSA-001, Velusetrag, Camicinal, VLY-686 (Tradipitant), GM-611, and several additional emerging therapies.
Gastroparesis Emerging Drugs Profile
NG101: Neurogastrx, Inc.
NG101 is an oral, small-molecule, peripherally acting dopamine D2 receptor antagonist. While D2 receptor antagonists have shown effectiveness in alleviating Gastroparesis symptoms, their clinical utility has often been restricted due to risks of central nervous system and cardiac adverse effects.
NG101 represents a proprietary mesylate salt form of metopimazine, a D2 receptor antagonist with a long-standing safety record. Metopimazine has been approved and prescribed in France for more than four decades for treating nausea and vomiting and has demonstrated favorable tolerability. Importantly, it has not been linked to significant CNS or cardiac safety concerns. NG101 is currently in Phase II clinical development for Gastroparesis treatment.
Yuhan Corporation (developer of YH12852 / PCS12852)
Candidate: PCS12852 Affiliation: Initially developed by Yuhan Corp (Korea); licensed to Processa Pharmaceuticals (US) for clinical advancement. Clinical Phases: Completed Phase 2a gastroparesis human trial; planned Phase 2b. MOA: Selective 5-HT4 serotonin receptor agonist — prokinetic action improving gastric emptying and symptoms. Trial Registry:
- Phase 2a trial (clinicaltrials.gov identifier NCT05270460) conducted under Processa sponsorship in the US — originally Yuhan licensed to Processa. Latest Developments / Regulatory:
- PCS12852 demonstrated safety, tolerability, and gastroparesis symptom improvements in Phase 2a. Processa continues plans for a Phase 2b development in 2025–2026.
- A binding licensing term sheet was signed in June 2025 for global GI indication advancement, with substantial potential milestone payments tied to success
CIN-102: CinDome Pharma, Inc.
CIN-102 (Deudomperidone) is an innovative, deuterated formulation of a dopamine D2/D3 receptor antagonist designed to enhance safety while preserving therapeutic efficacy. Domperidone, widely used outside the United States for nausea, vomiting, and Gastroparesis, has faced regulatory restrictions in the US due to QT prolongation concerns.
Deudomperidone has been engineered to optimize pharmacokinetics, offering sustained therapeutic benefit while significantly minimizing cardiac risk. Clinical studies to date have shown the therapy to be well tolerated, with no sponsor-assessed drug-related adverse events or clinically meaningful laboratory abnormalities. A thorough QT study demonstrated no significant QT impact at exposures exceeding therapeutic levels. Additionally, previous trials showed improved gastric emptying times and confirmed target engagement. CIN-102 is currently progressing through Phase II development for Gastroparesis.
Capeserod: Entero Therapeutics, Inc.
Capeserod is a selective 5-HT4 receptor partial agonist being repositioned for multiple gastrointestinal disorders. The 5-HT4b receptor subtype is expressed within the human GI tract, and activation may stimulate peristaltic reflexes and enhance secretory activity through neurotransmitter release.
By potentially reducing colonic transit time and improving motility, capeserod offers promise in addressing Gastroparesis symptoms. The therapy is presently in Phase I clinical development
Insights Delivered by the Gastroparesis Pipeline Report
The report provides extensive analysis of companies developing Gastroparesis therapies, including aggregated drug portfolios by organization.
- Segmentation of therapeutic candidates into early-, mid-, and late-stage development categories.
- Evaluation of active, dormant, and discontinued projects across the Gastroparesis landscape.
- Detailed assessment of pipeline drugs by stage, mechanism of action, target receptor, route of administration, monotherapy versus combination strategy, and molecular class.
- In-depth analysis of collaborations, licensing agreements, and financing activities supporting market expansion.
Stay informed about the next wave of innovation in Gastroparesis. Review DelveInsight’s full pipeline intelligence report to identify strategic opportunities and clinical advancements: https://www.delveinsight.com/report-store/gastroparesis-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=mpr
Gastroparesis Companies
Neurogastrx Inc., Dr. Falk Pharma GmbH, CinDome Pharma Inc., Entero Therapeutics Inc., RaQualia Pharma, and additional emerging biotech and pharmaceutical players are actively contributing to the evolving Gastroparesis therapeutic landscape.
Gastroparesis Pipeline Categorization by Route of Administration (ROA)
Pipeline therapies are classified across multiple administration routes, including:
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Gastroparesis Pipeline Categorization by Molecule Type
Therapeutic candidates are segmented by molecular class, such as:
- Recombinant fusion proteins
- Small molecules
- Monoclonal antibodies
- Peptides
- Polymers
- Gene therapies
Unlock critical intelligence on market drivers, barriers, and the long-term outlook of @ Gastroparesis therapies
Scope of the Gastroparesis Pipeline Report
Coverage
Global analysis
Gastroparesis Companies
Neurogastrx Inc., Dr. Falk Pharma GmbH, CinDome Pharma Inc., Entero Therapeutics Inc., RaQualia Pharma, and others.
Gastroparesis Pipeline Therapies
Tradipitant, PCS12852, Naronapride, CNSA-001, Velusetrag, Camicinal, VLY-686 (Tradipitant), GM-611, and additional investigational therapies.
Therapeutic Assessment by Product Type
- Monotherapy
- Combination therapy
- Mono/Combination approaches
Therapeutic Assessment by Clinical Stage
- Discovery
- Preclinical
- Phase I
- Phase II
- Phase III
Curious which innovators are shaping the future of Gastroparesis drug development? Explore DelveInsight’s in-depth @Gastroparesis Pipeline Report
Table of Contents
- Introduction
- Executive Summary
- Gastroparesis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Gastroparesis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- NG101: Neurogastrx, Inc.
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Capeserod: Entero Therapeutics, Inc.
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Gastroparesis Key Companies
- Gastroparesis Key Products
- Gastroparesis- Unmet Needs
- Gastroparesis- Market Drivers and Barriers
- Gastroparesis- Future Perspectives and Conclusion
- Gastroparesis Analyst Views
- Gastroparesis Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Mehul Malhotra Email: mmalhotra@delveinsight.com
Website: https://www.delveinsight.com